Viridian Pharma repliesBMJ 2010; 341 doi: https://doi.org/10.1136/bmj.c7010 (Published 07 December 2010) Cite this as: BMJ 2010;341:c7010
- Timothy J Rockley, medical director1
- 1Viridian Pharma, Newport, Gwent NP18 2AB, UK
In their open letter Nicholl and colleagues say that caffeine treatment for apnoea of prematurity has been subject to “massive” price rises in …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial